PURPOSE OF REVIEW: Remarkable insights have been gleaned recently with regard to the pathophysiology of IgG4-related disease (IgG4-RD). These findings have direct implications for the development of targeted strategies for the treatment of this condition. RECENT FINDINGS: Oligoclonal expansions of cells of both the B and T lymphocyte lineages are present in the blood of patients with IgG4-RD. Oligoclonal expansions of plasmablasts are a good biomarker for disease activity. An oligoclonally expanded population of CD4+ cytotoxic T lymphocytes is found not only in the peripheral blood but also at tissue sites of active disease. This cell elaborates cytokines that may drive the fibrosis characteristic of IgG4-RD. T follicular helper cells (Tfhc), particularly the Tfhc2 subset, appear to play a major role in driving the class switch to IgG4 that typifies this disease. The relationship between malignancy and IgG4-RD remains an area of interest. SUMMARY: Advances in understanding the pathophysiology of IgG4-RD have proceeded swiftly, leading to the identification of a number of potential targeted treatment strategies. The completion of classification criteria for IgG4-RD, an effort supported jointly by the American College of Rheumatology and the European League Against Rheumatism, will further facilitate studies on this disease.
PURPOSE OF REVIEW: Remarkable insights have been gleaned recently with regard to the pathophysiology of IgG4-related disease (IgG4-RD). These findings have direct implications for the development of targeted strategies for the treatment of this condition. RECENT FINDINGS: Oligoclonal expansions of cells of both the B and T lymphocyte lineages are present in the blood of patients with IgG4-RD. Oligoclonal expansions of plasmablasts are a good biomarker for disease activity. An oligoclonally expanded population of CD4+ cytotoxic T lymphocytes is found not only in the peripheral blood but also at tissue sites of active disease. This cell elaborates cytokines that may drive the fibrosis characteristic of IgG4-RD. T follicular helper cells (Tfhc), particularly the Tfhc2 subset, appear to play a major role in driving the class switch to IgG4 that typifies this disease. The relationship between malignancy and IgG4-RD remains an area of interest. SUMMARY: Advances in understanding the pathophysiology of IgG4-RD have proceeded swiftly, leading to the identification of a number of potential targeted treatment strategies. The completion of classification criteria for IgG4-RD, an effort supported jointly by the American College of Rheumatology and the European League Against Rheumatism, will further facilitate studies on this disease.
Authors: Arezou Khosroshahi; Mollie N Carruthers; Vikram Deshpande; Sebastian Unizony; Donald B Bloch; John H Stone Journal: Medicine (Baltimore) Date: 2012-01 Impact factor: 1.889
Authors: Hamid Mattoo; Vinay S Mahajan; Takashi Maehara; Vikram Deshpande; Emanuel Della-Torre; Zachary S Wallace; Maria Kulikova; Jefte M Drijvers; Joe Daccache; Mollie N Carruthers; Flavia V Castelino; James R Stone; John H Stone; Shiv Pillai Journal: J Allergy Clin Immunol Date: 2016-03-11 Impact factor: 10.793
Authors: Joseph P Casazza; Michael R Betts; David A Price; Melissa L Precopio; Laura E Ruff; Jason M Brenchley; Brenna J Hill; Mario Roederer; Daniel C Douek; Richard A Koup Journal: J Exp Med Date: 2006-12-11 Impact factor: 14.307
Authors: Melanie A Ruffner; Alex Hu; Julianna Dilollo; Kassidy Benocek; Donna Shows; Michael Gluck; Jonathan M Spergel; Steven F Ziegler; David A Hill; Karen Cerosaletti Journal: J Immunol Date: 2021-02-08 Impact factor: 5.422
Authors: Ibnouf Sulieman; Ahmed Mahfouz; Einas AlKuwari; Lajos Szabados; Walid Elmoghazy; Ahmed Elaffandi; Hatem Khalaf Journal: Int J Surg Case Rep Date: 2018-07-31